Payment overview · 2025
General Payments
$496.91
4 reported records · 3 companies
Healthcare provider profile · identity verified
Julie E. Sudduth, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · THE VILLAGES, FL · NPI 1326060716
Verified facts
What the public records show
CMS Open Payments records show Julie E. Sudduth, D.O. received $496.91 in general payments during 2025 across 4 reported records.
Lilly USA, LLC accounted for 49.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $244.89 | 49.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $130.81 | 26.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $121.21 | 24.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $496.91 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $130.81 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $130.81 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $121.89 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $121.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 575 | 178 |
| Levothyroxine Sodium | Levothyroxine Sodium | 553 | 164 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 530 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 395 | 121 |
| Losartan Potassium | Losartan Potassium | 381 | 117 |
| Lisinopril | Lisinopril | 288 | 90 |
| Omeprazole | Omeprazole | 232 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 210 | 70 |
| Simvastatin | Simvastatin | 180 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 57 |
| Alprazolam | Alprazolam | 150 | 56 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 149 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 40 |
| Methylprednisolone | Methylprednisolone | 135 | 118 |
| Trazodone Hcl | Trazodone Hcl | 133 | 39 |
| Metformin Hcl | Metformin Hcl | 132 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 118 | 33 |
| Sertraline Hcl | Sertraline Hcl | 118 | 35 |
| Gabapentin | Gabapentin | 113 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 36 |
| Bupropion Xl | Bupropion Hcl | 106 | 33 |
| Famotidine | Famotidine | 103 | 44 |
| Meloxicam | Meloxicam | 88 | 35 |
| Alendronate Sodium | Alendronate Sodium | 85 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 25 |
| Ozempic | Semaglutide | 85 | 19 |
| Montelukast Sodium | Montelukast Sodium | 83 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 32 |
| Atenolol | Atenolol | 76 | 22 |
| Potassium Chloride | Potassium Chloride | 76 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 20 |
| Estradiol | Estradiol | 65 | 27 |
| Tramadol Hcl | Tramadol Hcl | 65 | 34 |
| Azithromycin | Azithromycin | 61 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 19 |
| Furosemide | Furosemide | 58 | 24 |
| Carvedilol | Carvedilol | 56 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 18 |
| Eliquis | Apixaban | 55 | 22 |
| Amoxicillin | Amoxicillin | 54 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 27 |
| Allopurinol | Allopurinol | 50 | 17 |
| Glipizide Er | Glipizide | 48 | 14 |
| Metformin Hcl Er | Metformin Hcl | 46 | 17 |
| Synthroid | Levothyroxine Sodium | 46 | 14 |
| Baclofen | Baclofen | 45 | 14 |
| Celecoxib | Celecoxib | 45 | 16 |
| Ezetimibe | Ezetimibe | 45 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 19 |
| Myrbetriq | Mirabegron | 44 | 19 |
| Lorazepam | Lorazepam | 43 | 23 |
| Diazepam | Diazepam | 41 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 12 |
| Clonazepam | Clonazepam | 40 | 16 |
| Fenofibrate | Fenofibrate | 40 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 15 |
| Valsartan | Valsartan | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 24 | 20 |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | 15 |
| Valacyclovir | Valacyclovir Hcl | 23 | 14 |
| Donepezil Hcl | Donepezil Hcl | 22 | 11 |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | 14 |
| Finasteride | Finasteride | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $496.91 · 4 records | Lilly USA, LLC | DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Wegovy, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error